A Transcriptomic Biomarker to Quantify Systemic Inflammation in Sepsis - A Prospective Multicenter Phase II Diagnostic Study

EBioMedicine

Volumn 6, Issue , 2016, Pages 114-125

  Bauer, Michael ^a   Giamarellos Bourboulis, Evangelos J ^a,b   Kortgen, Andreas ^a   Möller, Eva ^c   Felsmann, Karen ^c   Cavaillon, Jean Marc ^d   Guntinas Lichius, Orlando ^a   Rutschmann, Olivier ^e   Ruryk, Andriy ^a   Kohl, Matthias ^f   Wlotzka, Britta ^g   Rußwurm, Stefan ^a   Marshall, John C ^h   Reinhart, Konrad ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Sepsis diagnostics expert group   (Germany)

^d INSTITUT PASTEUR   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f FURTWANGEN UNIVERSITY   (Germany)

^g State Development Corporation of Thuringia   (Germany)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Adaptive immunity; Clinical utility; Host response; Point of care; RT qPCR; Transcriptomic profiling

Indexed keywords

C REACTIVE PROTEIN; CARBOXYPEPTIDASE; CD59 ANTIGEN; CLUSTERIN; FIBRINOGEN; INTERLEUKIN 7 RECEPTOR; PROCALCITONIN; TOLL LIKE RECEPTOR 5; TRANSCRIPTOME; GENETIC MARKER;

APACHE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; VENTILATOR ASSOCIATED PNEUMONIA; ADAPTIVE IMMUNITY; CLINICAL TRIAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; POINT OF CARE SYSTEM; PROCEDURES; PROGNOSIS;

ADAPTIVE IMMUNITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; IMMUNITY, INNATE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POINT-OF-CARE SYSTEMS; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEPSIS;

EID: 84962191128     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.03.006     Document Type: Article

References (35)

1. Adhikari N.K., Fowler R.A., Bhagwanjee S., Rubenfeld G.D. Critical care and the global burden of critical illness in adults. Lancet 2010, 376:1339-1346.
2. Adib-Conquy M., Cavaillon J.M. Compensatory anti-inflammatory response syndrome. Thromb. Haemost. 2009, 101:36-47.
3. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 9:1303-1310.
4. Bo L., Wang F., Zhu J., Li J., Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 2011, 15:R58.
5. Boomer J.S., To K, Chang K.C., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594605.
6. Boomer J.S., Green J.M., Hotchkiss R.S. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. Virulence 2014, 5:45-56.
7. Calandra T., Cohen J. The International Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit. Care Med. 2005, 33:1639-1648.
8. Calvano S.E., Xiao W., Richards D.R., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
9. Cohen J., Vincent J.L., Adhikari N.K., et al. Sepsis: a roadmap for future research. Lancet Infect. Dis. 2015, 15:581-614.
10. Desai K.H., Tan C.S., Leek J.T., Maier R.V., Tompkins R.G., Storey J.D. Dissecting inflammatory complications in critically injured patients by within-patient gene expression changes: a longitudinal clinical genomics study. PLoS Med. 2011, 8.
11. Feezor R.J., Cheng A., Paddock H.N., Baker H.V., Moldawer L.L. Functional genomics and gene expression profiling in sepsis: beyond class prediction. Clin. Infect. Dis. 2005, 41:S427-S435.
12. Giamarellos-Bourboulis E.J., Raftogiannis M. The immune response to severe bacterial infections: consequences for therapy. Exp. Rev. Anti-Infect. Ther. 2012, 10:369-380.
13. Gomez H.G., Gonzalez S.M., Londoño J.M., et al. Immunological characterization of compensatory anti-inflammatory response syndrome in patients with severe sepsis: a longitudinal study. Crit. Care Med. 2014, 42:771-780.
14. Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 2013, 13:260-268.
15. Johnson S.B., Lissauer M., Bochiccchio G.V., et al. Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann. Surg. 2007, 245:611-621.
16. Kaukonen K.M., Bailey M., Pilcher D., Cooper D.J., Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N. Engl. J. Med. 2015, 372:1629-1638.
17. Kenneth J.L., Thomas D.S. Analysis of relative gene expression data using real-time quantitative PCR and the δδCT method. Methods 2001, 25:402-408.
18. Kumar G., Kumar A., Taneja A., et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011, 140:122331.
19. Levy M., Fink M.P., Marshall J.C., et al. SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit. Care Med. 2001, 31:1250-1256. (2003).
20. Lissauer M.E., Johnson S.B., Bochicchio G.V., et al. Differential expression of Toll-like receptor genes: sepsis compared with sterile inflammation 1 day before sepsis diagnosis. Shock 2009, 31:238-244.
21. McHugh L., Seldon T.A., Brandon R.A., et al. A molecular host response assay to discriminate between sepsis and infection-negative systemic inflammation in critically ill patients: discovery and validation in independent cohorts. PLoS Med. 2015, 12.
22. Medzhitov R., Schneider D.S., Soares M.P. Disease tolerance as a defense strategy. Science 2012, 335:936-941.
23. Montague E., Stanberry L., Higdon R., et al. MOPED 2.5-an integrated multi-omics resource: multi-omics profiling expression database now includes transcriptomics data. OMICS 2014, 18:335-343.
24. Opal S.M., Calandra T. Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients?. JAMA 2009, 302:2367-2368.
25. Ozdemir V., Williams-Jones B., Glatt S.J., et al. Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 2006, 24:942-946.
26. Parnell G.P., Tang B.M., Nalos M., et al. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions. Shock 2013, 40:166-174.
27. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit. Care 2010, 14:R15.
28. Scicluna B.P., Klein Klouwenberg P.M., van Vught L.A., et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am. J. Respir. Crit. Care Med. 2015, 192:826-835.
29. Singer M., Glynne P. Treating critical illness: the importance of first doing no harm. PLoS Med. 2005, 2.
30. Singer M., Deutschman C.S., Seymour C.W., et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016, 315:801-810.
31. Tang B.M., McLean A.S., Dawes I.W., Huang S.J., Lin R.C. The use of gene-expression profiling to identify candidate genes in human sepsis. Am. J. Respir. Crit. Care Med. 2007, 176:676-684.
32. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
33. Wong H.R., Lindsell C.J., Pettilä V., et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit. Care Med. 2014, 42:781-789.
34. Xiao W., Mindrinos M.N., Seok J., et al. A genomic storm in critically injured humans. J. Exp. Med. 2011, 208:2581-2590.
35. Zhang Q., Raoof M., Chen Y., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.